Active ingredientTolcaponeCat. No. P-T150-001CAS 134308-13-7Family · Pharmaceutical analytical standards
Tolcapone
An inhibitor of COMT, the enzyme that breaks down levodopa: introduced in Europe in 1997 and in the United States in 1998, it is used alongside levodopa in Parkinson's disease to prolong its effect. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.
Did you know?It is an intensely yellow, odourless and bitter crystalline powder: its metabolites, also yellow, can harmlessly colour the urine.
Go to the active ingredient →Active ingredientTolcaponeCat. No. P-T150-001CAS 134308-13-7
Pharmacopoeial impurityTolcapone USP Related Compound ACat. No. P-T150-002CAS 1391053-03-4
Pharmacopoeial impurityTolcapone USP Related Compound BCat. No. P-T150-003CAS 134612-80-9
MetaboliteTolcapone 3-beta-D-GlucuronideCat. No. P-T150-004CAS 204853-33-8
Isotopically labelled3-O-Methyl Tolcapone-d4Cat. No. P-T150-005
Isotopically labelledTolcapone-d4Cat. No. P-T150-006CAS 1246816-93-2
ImpurityHydroxymethyl O-Sulfate TolcaponeCat. No. P-T150-007
ImpurityO-sulphate TolcaponeCat. No. P-T150-008
ImpurityTolcapone Impurity 1Cat. No. P-T150-009No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.